Respiratory Failure Management

Introduction to Hypercapnic Respiratory Failure

• Hypercapnic respiratory failure is characterized by a PaCO₂ above 6.1 kPa (46 mmHg), indicating type 2 respiratory failure, according to the British Thoracic Society 1
• The primary mechanisms leading to hypercapnia include alveolar hypoventilation, increased CO₂ in inspired gas, increased carbon dioxide production, and increased external dead space, as stated by the British Thoracic Society and the European Respiratory Society 1, 2

Patient Risk Factors

• Patients with underlying COPD are at highest risk for developing hypercapnia 1
• Other conditions such as obesity hypoventilation syndrome, neuromuscular disorders, chest wall deformities, and bronchiectasis are also at risk of hypercapnia 1, 3
• Central nervous system depression, such as medullary respiratory center depression by drugs/sedatives, head injury, or intracerebral hemorrhage, can lead to hypercapnia 1

Oxygen Therapy

• For patients with known COPD or risk of hypercapnic respiratory failure, the American Thoracic Society recommends targeting oxygen saturation of 88-92% 1
• Controlled oxygen delivery via 24% or 28% Venturi mask or 1-2 L/min nasal cannula is recommended for patients with known COPD or risk of hypercapnic respiratory failure 1
• Excessive oxygen administration should be avoided in at-risk patients as it can worsen hypercapnia, as suggested by the European Respiratory Society 3
• For patients without risk of hypercapnic respiratory failure, targeting oxygen saturation of 94-98% is recommended 1

Monitoring and Interventions

• Recheck blood gases after 30-60 minutes of oxygen therapy initiation to assess for hypercapnia 1
• Monitor for clinical deterioration, including increasing respiratory rate and decreasing level of consciousness, in patients with hypercapnic respiratory failure 1
• Consider intubation and mechanical ventilation if respiratory rate exceeds 30 breaths/min, severe acidosis (pH <7.25) is present, or non-invasive ventilation (NIV) fails or is contraindicated 4
• Consideration of NIV is recommended if pH <7.35, PaCO₂ ≥6.5 kPa, and respiratory rate >23 breaths/min persist after optimal medical therapy, according to the British Thoracic Society and the European Respiratory Society 1, 2

Diagnostic Criteria

Contraindications and Precautions

• High-Flow Nasal Oxygen (HFNO) should not be used in patients with hypercapnia from obstructive lung disease or cardiogenic pulmonary edema 4
• Oxygen therapy should never be abruptly discontinued in hypercapnic patients as this can cause life-threatening rebound hypoxemia 1
• Delaying non-invasive ventilation (NIV) in appropriate candidates can lead to worsening respiratory failure requiring intubation 3

Non-Invasive Ventilation

• NIV should be considered in patients with neuromuscular or chest wall disease when vital capacity is <1L and respiratory rate >20, even if they are normocapnic, according to the American College of Chest Physicians 5
• Intubation should be considered if the respiratory rate exceeds 30 breaths/min, especially if there is severe acidosis (pH <7.25), as stated by the European Respiratory Society 2